EVALUATION OF THE ACTION OF STATINS IN THERAPEUTIC MANAGEMENT OF DIABETIC DYSLIPIDEMIA, CASES OF TYPE 2 DIABETES IN LUBUMBASHI

Context Type 2 diabetes is preceded by a long asymptomatic phase that is often overlooked, but in which the body undergoes many changes. Diabetics have a significantly increased risk of cardiovascular diseases such as angina, heart attack, stroke or peripheral vascular disease. These complications of diabetes affecting large arteries are the particular consequences of dyslipidemia. Goal The objective of this study was to evaluate the effectiveness of statin group of drugs used in the drug management of dyslipidemia of type 2 diabetes in the city of Lubumbashi in the Democratic Republic of Congo. Methods This is a cross-sectional study conducted from June to December 2014 in Lubumbashi (DR Congo). 40 patients with type 2 confused sex with 20 drugs in the statin family, fibrates under 10 and 10 in the statin-fibrate combination were in this descriptive study. Alongside the classical laboratory tests, analysis of lipid parameters were carried out: HDL cholesterol, LDL cholesterol, total cholesterol and triglyceride. Results Different levels of serum lipids were analyzed recorded based on lipid-lowering therapy. Type 2 diabetes, obese of the first class, who were treated with combination statin + fibrate, presented at least one month after treatment a normal lipid levels in all respects. Conclusion Statins are potent molecules able to stabilize lipids. However these drugs are sometimes ineffective in the treatment of dyslipidemia in type 2 diabetes when used as monotherapy. Hence the need to add to them other molecules to enhance their lipid-lowering effect through a synergy of action.